Alnylam Pharmaceuticals
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03862807
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03841448
- Locations
- π¬π§
Clinical Trial Site, Leicester, United Kingdom
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
Terminated
- Conditions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03774784
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03767829
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 164
- Registration Number
- NCT03759379
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT03681184
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 212
- Registration Number
- NCT03547297
- Locations
- πΊπΈ
Clinical Trial Site, Salt Lake City, Utah, United States
A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03505853
- Locations
- πΈπͺ
Clinical Trial Site, Stockholm, Sweden
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT03350451
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 94
- Registration Number
- NCT03338816
- Locations
- π¬π§
Clinical Trial Site, London, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath